MAPT and Alzheimer disease: Interconnections between cholinergic abnormalities and other pathophysiological features of AD, such as abnormal A and tau cascade, point to the development of novel multi-drug ligands (MTDL), as the pharmacophoric functions responsible for AChE inhibition could be combined with pharmacophoric fragments thought to interact with BACE-1.